Senolytics: the science of eliminating the zombie cells that age you

Picture an office where some employees stopped doing any real work years ago. They don't quit, they don't get fired, but they don't produce anything useful either. What they do produce is a constant stream of toxic emails — complaints, gossip, negativity that drags everyone else down. In biology, that's exactly what senescent cells do inside your body. Scientists call them "zombie cells," and fifteen years of research have shown that eliminating them may be one of the most direct strategies to slow aging.

Senolytics are compounds designed to selectively destroy these zombie cells. The field has moved from laboratory mice to the first clinical trials in humans, and the results are solid enough for Nature Medicine to call this one of the most relevant advances in gerontology of the 21st century.

What are senescent cells?

A senescent cell is one that has permanently stopped dividing but refuses to die. Under normal conditions, when a cell is damaged or aged it has two options: repair itself and keep working, or activate a self-destruction program called apoptosis. Senescent cells dodge that program. They stay, take up space, and secrete a cocktail of inflammatory substances known as SASP (Senescence-Associated Secretory Phenotype).

The SASP includes pro-inflammatory cytokines (IL-6, IL-8, TNF-α), matrix metalloproteinases that degrade surrounding tissue, growth factors that alter the local microenvironment, and chemokines that recruit immune cells. In practical terms, it is a constant alarm signal that inflames everything around it.

This mechanism is not an evolutionary mistake. In young people, cellular senescence serves useful functions: it stops potentially cancerous cells from multiplying, participates in wound healing, and contributes to embryonic development. The problem is that a young immune system clears senescent cells efficiently. After age 40-50, that clearance capacity declines. Zombie cells accumulate. And with them, inflammation.

By age 60, the senescent cell burden in tissues like fat, skin, lung, and joints can multiply 5-10 fold compared to a 30-year-old. That finding, documented by Xu et al. in Nature Medicine (2018), partly explains why so many diseases cluster in the second half of life.

How zombie cells accelerate aging

Senescent cell accumulation is not just a marker of aging — it is a driver of aging. The SASP they secrete generates a state of chronic low-grade inflammation that the scientific community calls inflammaging. This persistent inflammation damages healthy neighboring tissues and can push normal cells into senescence, creating a domino effect.

The documented connections between cellular senescence and disease are extensive:

• Neurodegenerative diseases: senescent cells in the brain secrete factors that promote the accumulation of tau proteins (Alzheimer's) and alpha-synuclein (Parkinson's). A study by Bussian et al. (Nature, 2018) demonstrated that removing senescent cells in Alzheimer's model mice reduced tau pathology and neurodegeneration.
• Type 2 diabetes: senescent cells in adipose and pancreatic tissue disrupt insulin signaling and promote insulin resistance through IL-6 and TNF-α.
• Cardiovascular disease: senescence in the vascular endothelium and atherosclerotic plaques contributes to plaque instability. Childs et al. (Science, 2016) showed that clearing senescent cells in mice reduced atherosclerosis.
• Osteoarthritis: joints accumulate senescent cells that degrade cartilage and perpetuate joint inflammation. Senolytics in animal models of osteoarthritis improved joint function and reduced pain.
• Pulmonary fibrosis: the lungs of patients with idiopathic pulmonary fibrosis show massive senescent cell accumulation. This was precisely the disease in which the first senolytic clinical trial in humans took place.
• Cancer: paradoxically, while senescence stops cell proliferation (an anti-cancer effect), the SASP can create a microenvironment that promotes tumor growth in neighboring non-senescent cells.

The common denominator is the SASP. As Franceschi described in his inflammaging framework, chronic systemic inflammation is the terrain where age-related diseases take root. Senescent cells are one of the primary sources of that inflammation.

What are senolytics?

The term comes from the Latin senex (old) and Greek lysis (destruction). Senolytics are compounds that selectively induce cell death in senescent cells without harming healthy ones. The idea sounds simple; the execution is anything but.

Senescent cells survive because they activate anti-apoptotic pathways — they essentially reinforce their defenses against programmed cell death. Senolytics attack precisely those defenses. The main compounds under investigation are:

• Dasatinib + Quercetin (D+Q): the first senolytic combination identified. Dasatinib is a tyrosine kinase inhibitor (approved as a chemotherapy drug for leukemia) and quercetin is a flavonoid found in onions, apples, and green tea. Together, each targets different survival pathways in different types of senescent cells. In old mice, D+Q improved physical function and extended remaining lifespan by 36% (Xu et al., Nature Medicine, 2018).
• Fisetin: a natural flavonoid found in strawberries, apples, persimmons, and onions. Yousefzadeh et al. (EBioMedicine, 2018) demonstrated that fisetin was the most potent natural senolytic among 10 flavonoids tested, extending lifespan and improving health in old mice. Its advantage: it's an over-the-counter supplement, though senolytic doses are far higher than dietary amounts.
• Navitoclax (ABT-263): a BCL-2 family inhibitor that targets anti-apoptotic proteins. Highly effective against hematopoietic senescence but with platelet toxicity that limits clinical use.
• Experimental drugs: UBX0101 (Unity Biotechnology, failed Phase II for knee osteoarthritis in 2020), UBX1325 (in development for macular degeneration), and an emerging generation of senolytics targeting more specific molecular pathways.

An important nuance: senolytics don't need to be given continuously. Since senescent cells don't divide, intermittent treatment (e.g., 3 days per month or periodic cycles) may be enough to keep the senescent burden low. This dramatically reduces the risk of side effects.

Senolytics in humans: where are we?

The transition from mice to humans is underway, with promising but still preliminary results. Being honest about the current state is essential.

What has been tested in humans

Pulmonary fibrosis (2019): Justice et al. published in EBioMedicine the first senolytic clinical trial in humans. 14 patients with idiopathic pulmonary fibrosis received D+Q (dasatinib 100 mg + quercetin 1,000 mg) for 3 consecutive days per week, for 3 weeks. Results: significant improvement in 6-minute walk distance (+21.5 meters), gait speed, and the chair-stand test. Side effects were mild (gastrointestinal). No serious complications occurred.

Diabetic kidney disease (2019): Hickson et al. (EBioMedicine) confirmed in 9 patients that D+Q reduced senescent cells in adipose tissue measured by p16 and p21 markers, and decreased circulating SASP cytokines. This was the first direct demonstration that senolytics work at the tissue level in humans.

Mild cognitive impairment (2025): a recent trial of D+Q in patients with mild cognitive impairment showed safety and tolerability, with preliminary signals of reduced inflammatory markers in cerebrospinal fluid. Full results are pending publication.

What hasn't worked (yet)

UBX0101 (Unity Biotechnology): in 2020, this injectable senolytic failed a Phase II trial for knee osteoarthritis. It did not outperform placebo in pain reduction. It was a blow to the field, though with important caveats: the drug was administered locally (not systemically), the dose may have been insufficient, and the trial design was criticized. Unity redirected its efforts toward ocular diseases.

What's missing

Randomized, placebo-controlled trials with large sample sizes (hundreds of participants) confirming sustained clinical benefits. Most human data comes from pilot trials with 9-14 patients. Promising, but not definitive. Fisetin has an additional challenge: as a non-patentable supplement, there's no financial incentive for pharmaceutical companies to fund large trials. Existing studies are funded by academic institutions like Mayo Clinic.

The bottom line: pharmacological senolytics work remarkably well in mice. In humans, initial signals are positive, safety seems acceptable with intermittent dosing, but we need more data. Anyone promising you can "buy senolytics and get younger today" is getting ahead of the science.

Natural strategies against cellular senescence

While pharmacology advances, there are interventions you can implement now with solid evidence of reducing senescent cell accumulation or their effects:

Exercise: the best senolytic that exists

This is not hyperbole. Aerobic and strength exercise reduces markers of cellular senescence in muscle, fat, and blood. A 2023 meta-analysis confirmed that regular exercise decreases circulating levels of IL-6, TNF-α, and C-reactive protein — the same SASP markers. The mechanism includes autophagy activation (cellular cleanup), improved immune function (senescent cell clearance by NK cells), and reduction of visceral fat (the main reservoir of senescent cells).

Intermittent fasting and autophagy

Fasting activates autophagy, the cellular recycling program that eliminates damaged components. While autophagy doesn't directly kill whole senescent cells (that requires apoptosis), it does reduce the accumulation of misfolded proteins and dysfunctional organelles that contribute to the transition toward senescence. 16:8 or periodic 24-hour fasting protocols have the best evidence. De Cabo and Mattson reviewed this extensively in The New England Journal of Medicine (2019).

Anti-senescence nutrition

Several food compounds act as senolytics or senomorphics (they reduce the SASP without killing the cell):

• Quercetin: red onions, apples, broccoli, green tea. A direct senolytic when combined with dasatinib; senomorphic on its own.
• Fisetin: strawberries (the most concentrated source), apples, persimmons, cucumbers.
• Curcumin: turmeric. Reduces SASP expression through NF-κB inhibition.
• EGCG (epigallocatechin gallate): green tea. Documented senomorphic effects.
• Sulforaphane: broccoli, Brussels sprouts, kale. Activates Nrf2 and protects against oxidative stress that induces senescence.

Dietary doses are lower than the therapeutic amounts used in studies, but an anti-inflammatory diet rich in these compounds promotes a cellular environment less favorable to senescence.

Restorative sleep

Chronic sleep deprivation accelerates cellular senescence. Carroll et al. (Brain, Behavior, and Immunity, 2016) documented that sleeping less than 6 hours increases senescence markers in immune cells. Deep sleep is when DNA repair mechanisms and brain autophagy (glymphatic system) activate.

Clinical treatments that fight senescence

At a longevity clinic, the anti-senescence strategy isn't based on a single treatment. It's an integrated approach where multiple interventions attack the problem from complementary angles:

• Intravenous NAD+: NAD+ levels decline with age, compromising sirtuin function — epigenetic regulators involved in DNA repair and stress resistance. NAD+ supplementation reinforces cellular defense mechanisms against the transition to senescence. At Progevita, NAD+ IV therapy is part of programs starting from the Optimization Path (from €1,350).
• Ozone therapy: medical ozone therapy generates controlled oxidative stress that activates endogenous antioxidant defenses (Nrf2, SOD, glutathione). This hormetic effect protects healthy cells against the damage that leads to senescence.
• Plasmapheresis: therapeutic plasmapheresis directly removes circulating SASP cytokines and factors from the plasma. Mehdipour et al. (2022) demonstrated that therapeutic plasma exchange reduced p16 levels in immune cells — a direct senescence marker — and rejuvenated the immune profile.
• Hyperbaric chamber: the study by Hadanny et al. (Aging, 2020) with 35 adults over 64 showed that 60 hyperbaric oxygen sessions reduced senescent cells by 11-37% and lengthened telomeres by 20-38%. To date, this is the first non-pharmacological intervention to achieve both results simultaneously in humans.

Progevita's approach is to combine these modalities within a personalized program designed around individual biomarkers and a biological age profile. Not every patient needs everything: the program adapts to each person's profile, assessed by a team of over 50 medical professionals.

Frequently asked questions

Can I buy senolytics?

Quercetin and fisetin are sold as dietary supplements in health stores and online. Dasatinib is a prescription drug (approved for leukemia). Buying supplements is legal; what doesn't exist yet is medical consensus on optimal senolytic doses, frequency, or protocols for healthy individuals. Self-medicating with dasatinib without medical supervision is risky and inadvisable.

Are senolytics safe?

In published clinical trials (pulmonary fibrosis, diabetic kidney disease), D+Q given intermittently (3 days/week, short cycles) showed an acceptable safety profile, with mild gastrointestinal side effects. The long-term profile is unknown. Quercetin and fisetin as supplements have an excellent safety profile at standard doses.

At what age should I worry about senescent cells?

Significant accumulation begins at 40-50 years, with exponential acceleration after 60. Prevention strategies (exercise, diet, sleep, stress management) are relevant from age 30. Specific clinical interventions are evaluated individually based on biomarkers.

How much does anti-senescence treatment cost?

There is no standard "anti-senescence treatment." At Progevita, programs that integrate anti-senescence strategies (NAD+ IV, ozone therapy, plasmapheresis, biomarkers) range from €1,350 (Optimization Path) to €2,850 (specialized programs). The initial evaluation is part of the program.

What's the difference between a senolytic and a senomorphic?

A senolytic kills the senescent cell. A senomorphic reduces the harmful effects of the senescent cell (suppresses the SASP) without destroying it. Both approaches are complementary. Many natural compounds (curcumin, EGCG) act more as senomorphics than senolytics.

References

1. Baker DJ et al., "Naturally occurring p16(Ink4a)-positive cells shorten healthy lifespan", Nature, 2016 (DOI: 10.1038/nature16932)
2. Xu M et al., "Senolytics improve physical function and increase lifespan in old age", Nature Medicine, 2018 (DOI: 10.1038/s41591-018-0092-9)
3. Yousefzadeh MJ et al., "Fisetin is a senotherapeutic that extends health and lifespan", EBioMedicine, 2018 (DOI: 10.1016/j.ebiom.2018.09.015)
4. Justice JN et al., "Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study", EBioMedicine, 2019 (PMID: 30616998)
5. Hickson LJ et al., "Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin", EBioMedicine, 2019 (PMID: 31542391)
6. Childs BG et al., "Senescent intimal foam cells are deleterious at all stages of atherosclerosis", Science, 2016 (DOI: 10.1126/science.aaf6659)
7. Hadanny A et al., "Hyperbaric oxygen therapy increases telomere length and decreases immunosenescence in isolated blood cells", Aging, 2020 (DOI: 10.18632/aging.202188)
8. Mehdipour M et al., "Old plasma dilution reduces human biological age: a clinical study", GeroScience, 2022 (PMID: 35999337)

This article is for informational purposes only and does not replace medical advice. Pharmacological senolytics are in the experimental phase and should not be taken without professional supervision.

Want to assess your senescent cell burden and build a plan to reduce it? Talk to our medical team and evaluate your aging biomarkers at the Balneario de Cofrentes.